Sonia Anand, a professor of medicine and vascular medicine specialist at ‪@McMaster‬ in Canada, delves into the critical role of dual pathway inhibition in treating patients with peripheral artery disease (PAD). This comprehensive session highlights the significant findings from the COMPASS and Voyager trials, identifying which patients benefit most from this treatment approach.

Key Highlights:

Dual Pathway Inhibition Benefits: Understanding the importance of dual pathway inhibition, especially in patients with polyvascular disease.
HighRisk Patient Identification: Insights into identifying highrisk patients using modified REACH risk scoring and CART analysis.
Impact on HighRisk Groups: Examining the benefits of dual pathway inhibition in patients with polyvascular disease, heart failure, renal insufficiency, and diabetes.
MetaAnalysis of COMPASS and Voyager Trials: A detailed look at the net clinical benefits of dual pathway inhibition over aspirin in PAD patients.
Shared DecisionMaking Model: The importance of conveying risks and benefits clearly to patients for informed decisionmaking and adherence to treatment.

Who Should Watch:

Vascular medicine specialists, cardiologists, and healthcare professionals treating PAD.
Medical researchers and students interested in the latest advancements in vascular medicine.
Patients and caregivers looking to understand treatment options for PAD.

Stay Connected:

Follow us for more expert discussions: twitter.com/vascularcures
Learn more about vascular health on our website: vascularcures.org

Engage with Us:

Share your perspectives or questions in the comments section below.
Subscribe to our channel for more insightful content on vascular health and treatments.

#DualPathwayInhibition #PeripheralArteryDisease #VascularMedicine #COMPASSTrial #VoyagerTrial #PatientCare #MedicalResearch #HealthcareEducation

This video is intended for educational purposes only and does not serve as a substitute for professional medical advice.